Mithra Pharmaceuticals S.A. Logo

Mithra Pharmaceuticals S.A.

ISIN

BE0974283153

Ticker

MITRA

Sector

Health Care

Sub-Industry

Pharmaceuticals

Country

Belgium

Year Founded

1999

About Mithra Pharmaceuticals S.A.

Company Description

We are committed to providing women new choices improving their daily life

For over twenty years, Mithra has dedicated its researches so as to redefine women’s health by bringing innovative products in the fields of contraception and menopause.

Today, Mithra counts two complementary platforms: its portfolio of innovative products based on Estetrol (E4) and its portfolio of Complex Therapeutics. The whole supported by the Mithra CDMO, a technological platform offering a wide range of services going from pharmaceutical development to commercial manufacturing.

Since the launch of the first generic contraceptive pill in Belgium, Mithra always focused on innovation for women.

After years of research and development, our pipeline today includes late-stage development products, potential blockbusters and complex therapeutics in the fields of contraception and menopause. These projects are powered by our Mithra CDMO, our unique R&D and manufacturing platform.

Headcount

350

Served Area

Worldwide

Headquarters

Rue Saint-George 5
4000, Rocourt, Liège
Belgium

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 521,985,000.00 421,918,000.00 442,414,000.00
Noncurrent Assets N/A 283,509,000.00 322,528,000.00 296,552,000.00
Property Plant And Equipment N/A 29,921,000.00 38,354,000.00 40,717,000.00
Goodwill N/A 5,233,000.00 5,233,000.00 5,233,000.00
Intangible Assets Other Than Goodwill N/A 89,005,000.00 104,954,000.00 134,905,000.00
Deferred Tax Assets N/A 50,905,000.00 63,456,000.00 16,354,000.00
Noncurrent Derivative Financial Assets N/A 6,184,000.00 0.00 N/A
Other Noncurrent Assets N/A 14,401,000.00 9,263,000.00 9,544,000.00
Current Assets N/A 238,475,000.00 99,389,000.00 145,863,000.00
Inventories N/A 35,382,000.00 43,852,000.00 50,312,000.00
Trade And Other Current Receivables N/A 10,052,000.00 10,044,000.00 22,277,000.00
Cash and cash equivalents 49,720,000.00 138,675,000.00 32,872,000.00 28,285,000.00
Current Derivative Financial Assets N/A 2,881,000.00 100,000.00 0.00
Shortterm Deposits Not Classified As Cash Equivalents N/A 14,000.00 0.00 N/A
Equity And Liabilities N/A 521,985,000.00 421,918,000.00 442,414,000.00
Equity 163,298,000.00 157,737,000.00 33,840,000.00 33,687,000.00
Issued Capital N/A 31,271,000.00 32,250,000.00 41,228,000.00
Retained Earnings N/A -219,759,000.00 -336,633,000.00 -396,254,000.00
Other Reserves N/A 13,690,000.00 -2,545,000.00 -19,934,000.00
Additional Paidin Capital N/A 332,535,000.00 340,769,000.00 408,647,000.00
Noncurrent Liabilities N/A 293,500,000.00 292,285,000.00 278,298,000.00
Noncurrent Provisions N/A 266,000.00 266,000.00 266,000.00
Noncurrent Contract Liabilities N/A 3,706,000.00 0.00 N/A
Noncurrent Government Grants N/A 15,195,000.00 12,769,000.00 8,127,000.00
Deferred Tax Liabilities N/A 4,363,000.00 6,089,000.00 4,420,000.00
Other Noncurrent Financial Liabilities N/A 101,180,000.00 102,675,000.00 74,210,000.00
Noncurrent Derivative Financial Liabilities N/A 0.00 2,897,000.00 15,261,000.00
Longterm Borrowings N/A 111,898,000.00 113,608,000.00 127,052,000.00
Current Liabilities N/A 70,747,000.00 95,793,000.00 130,431,000.00
Trade And Other Current Payables N/A 27,272,000.00 23,331,000.00 58,082,000.00
Current Government Grants N/A 1,259,000.00 1,617,000.00 1,417,000.00
Other Current Financial Liabilities N/A 23,424,000.00 15,829,000.00 15,959,000.00
Current Derivative Financial Liabilities N/A 0.00 1,886,000.00 2,561,000.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 9,030,000.00 22,668,000.00 66,997,000.00
Other Income 6,574,000.00 4,809,000.00 7,196,000.00
Profit Loss From Operating Activities -83,678,000.00 -87,875,000.00 -26,245,000.00
Finance Income 1,782,000.00 2,838,000.00 9,852,000.00
Finance Costs 5,987,000.00 13,116,000.00 23,422,000.00
Profit Loss Before Tax -110,922,000.00 -123,769,000.00 -11,480,000.00
Income Tax Expense Continuing Operations -18,835,000.00 -6,895,000.00 48,139,000.00
Profit (loss) -92,086,000.00 -116,875,000.00 -59,620,000.00
Profit Loss Attributable To Owners Of Parent N/A -116,875,000.00 -59,620,000.00
Profit Loss Attributable To Noncontrolling Interests N/A 0.00 0.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -92,086,000.00 -116,875,000.00 -59,620,000.00
Adjustments For Decrease Increase In Inventories N/A -19,105,000.00 -8,470,000.00 -6,873,000.00
Adjustments For Sharebased Payments N/A 7,267,000.00 1,065,000.00 1,983,000.00
Cash Flows From Used In Operating Activities N/A -80,025,000.00 -76,788,000.00 -56,819,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A 23,000.00 0.00 169,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 10,645,000.00 11,483,000.00 6,356,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 5,585,000.00 9,699,000.00 19,302,000.00
Cash Flows From Used In Investing Activities N/A -16,207,000.00 -54,682,000.00 -25,490,000.00
Proceeds From Issuing Shares N/A 65,731,000.00 9,213,000.00 N/A
Payments Of Lease Liabilities Classified As Financing Activities N/A 3,475,000.00 7,193,000.00 6,663,000.00
Proceeds From Government Grants Classified As Financing Activities N/A 5,835,000.00 41,000.00 154,000.00
Interest Paid Classified As Financing Activities N/A 3,503,000.00 9,364,000.00 9,862,000.00
Cash Flows From Used In Financing Activities N/A 185,187,000.00 25,646,000.00 77,869,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 0.00 21,000.00 -147,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A 88,954,000.00 -105,824,000.00 -4,440,000.00
Cash and cash equivalents 49,720,000.00 138,675,000.00 32,872,000.00 28,285,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2021 - Q4 English 🇬🇧
  • Consolidated Report 2021 - Q4 French 🇫🇷

Insider Trades

Date Trading entity / Person Association Trade type Volume
17.01.2023 NOSHAQ SA Board Other EUR 617,814.92
17.11.2022 NOSHAQ SA Board Other EUR 1,052,701.40
18.07.2022 NOSHAQ SA Board Other EUR 1,006,250.00
13.05.2022 NOSHAQ SA Board Other EUR 1,239,062.50
13.04.2022 Gordenne Valérie Other Sell EUR 87,380.00
29.03.2022 Fornieri Francesco Board Sell EUR 1,312,000.00
25.03.2022 Fornieri Francesco Board Sell EUR 486,530.57
24.03.2022 Fornieri Francesco Board Sell EUR 219,536.19
24.03.2022 Fornieri Francesco Board Sell EUR 39,452.00
23.03.2022 Fornieri Francesco Board Sell EUR 178,230.75

Capital Markets Information

ISIN

BE0974283153

LEI

5493002FDD273HTEKK14

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Euronext Brussels

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.